Literature DB >> 7562598

Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.

M Hirai1, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda, T Komano.   

Abstract

P-glycoprotein modulators are respected to be multidrug resistance reversing agents in cancer chemotherapy. Some calcium channel blockers, calmodulin inhibitors or immunosuppressive agents have been used in clinical studies, although the dose of these drugs required to test in vitro experimental data might cause potent pharmacological effects which are not desirable in patients. By using LLC-GA5-COL150 cells that express P-glycoprotein specifically on the apical membranes, we examined the transport of anticancer drugs mediated by P-glycoprotein. Cepharanthin, a biscoclaurine alkaloid, potently inhibits the transport of vinblastine and daunorubicin, both commonly used anticancer agents. The 50% inhibitory concentration of cepharanthin on daunorubicin transport was 2.06 microM. Combined inhibitory effects on daunorubicin transport were observed when cepharanthin was used together with cyclosporin A, a potent immunosuppressive agent and P-glycoprotein modulator. Cepharanthin itself was transported by P-glycoprotein. Transcellular transport of cepharanthin across LLC-GA5-COL150 cell monolayers was saturable when its concentration was under 5 microM, and the transport was inhibited by P-glycoprotein modulators. These results indicate that cepharanthin can reverse multidrug resistance, and proper combination with other P-glycoprotein modulators could potentiate its inhibitory effect on expelling the anticancer drugs out of the cell via P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562598

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma.

Authors:  Mizuhiko Terasaki; Toshi Abe; Naohisa Miyagi; Etsuyo Ogo; Minoru Shigemori
Journal:  J Neurooncol       Date:  2006-08-26       Impact factor: 4.130

2.  Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein.

Authors:  K Tanaka; M Hirai; Y Tanigawara; M Yasuhara; R Hori; K Ueda; K Inui
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

3.  Prevention of lung metastasis by intra-tumoral injection of Cepharanthin and staphylococcal enterotoxin B in transplantable rat osteosarcoma.

Authors:  K Okada; N Sakusabe; A Kobayashi; N Hoshi; K Sato
Journal:  Jpn J Cancer Res       Date:  1999-09

4.  The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein.

Authors:  K Takara; Y Tanigawara; F Komada; K Nishiguchi; T Sakaeda; K Okumura
Journal:  Jpn J Cancer Res       Date:  2000-02

5.  Determination of cepharanthine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.

Authors:  Yingbin Deng; Weijun Wu; Sunzhi Ye; Wei Wang; Zhiyi Wang
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

6.  Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.

Authors:  N Kusunoki; K Takara; Y Tanigawara; A Yamauchi; K Ueda; F Komada; Y Ku; Y Kuroda; Y Saitoh; K Okumura
Journal:  Jpn J Cancer Res       Date:  1998-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.